Literature DB >> 35046520

Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.

Kyrillus S Shohdy1,2, Dario M Villamar3, Yen Cao4, Janson Trieu4, Kristin S Price5, Rebecca Nagy5, Scott T Tagawa1,6,7, Ana M Molina1,6,7, Cora N Sternberg1,6,7, David M Nanus1,6,7, Juan Miguel Mosquera6,7,8, Olivier Elemento6,9, Guru P Sonpavde10, Petros Grivas11, Nicholas J Vogelzang12, Bishoy Morris Faltas13,14,15,16.   

Abstract

BACKGROUND: Targeted sequencing of circulating tumour DNA (ctDNA) is a promising tool to monitor dynamic changes in the variant allele frequencies (VAF) of genomic alterations and predict clinical outcomes in patients with advanced urothelial carcinoma (UC).
METHODS: We performed targeted sequencing of 182 serial ctDNA samples from 53 patients with advanced UC.
RESULTS: Serial ctDNA-derived metrics predicted the clinical outcomes in patients with advanced UC. Combining serial ctDNA aggregate VAF (aVAF) values with clinical factors, including age, sex, and liver metastasis, improved the performance of prognostic models. An increase of the ctDNA aVAF by ≥1 in serial ctDNA samples predicted disease progression within 6 months in 90% of patients. The majority of patients with aVAFs ≤0.7 in three consecutive ctDNA samples achieved durable clinical responses (≥6 months).
CONCLUSIONS: Serial ctDNA analysis predicts disease progression and enables dynamic monitoring to guide precision medicine in patients with advanced UC.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35046520      PMCID: PMC8810988          DOI: 10.1038/s41416-021-01648-8

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy.

Authors:  Franz J Hilke; Francesc Muyas; Jakob Admard; Beate Kootz; Dominik Nann; Stefan Welz; Olaf Rieß; Daniel Zips; Stephan Ossowski; Christopher Schroeder; Kerstin Clasen
Journal:  Radiother Oncol       Date:  2020-07-17       Impact factor: 6.280

2.  Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Authors:  Neeraj Agarwal; Sumanta K Pal; Andrew W Hahn; Roberto H Nussenzveig; Gregory R Pond; Sumati V Gupta; Jue Wang; Mehmet A Bilen; Gurudatta Naik; Pooja Ghatalia; Christopher J Hoimes; Dharmesh Gopalakrishnan; Pedro C Barata; Alexandra Drakaki; Bishoy M Faltas; Lesli A Kiedrowski; Richard B Lanman; Rebecca J Nagy; Nicholas J Vogelzang; Kenneth M Boucher; Ulka N Vaishampayan; Guru Sonpavde; Petros Grivas
Journal:  Cancer       Date:  2018-03-08       Impact factor: 6.860

3.  Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study.

Authors:  Petros Grivas; Aly-Khan A Lalani; Gregory R Pond; Rebecca J Nagy; Bishoy Faltas; Neeraj Agarwal; Sumati V Gupta; Alexandra Drakaki; Ulka N Vaishampayan; Jue Wang; Pedro C Barata; Dharmesh Gopalakrishnan; Gurudatta Naik; Bradley A McGregor; Lesli A Kiedrowski; Richard B Lanman; Guru P Sonpavde
Journal:  Eur Urol Oncol       Date:  2019-03-09

4.  Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.

Authors:  Jean Sebastien Frenel; Suzanne Carreira; Jane Goodall; Desam Roda; Raquel Perez-Lopez; Nina Tunariu; Ruth Riisnaes; Susana Miranda; Ines Figueiredo; Daniel Nava-Rodrigues; Alan Smith; Christophe Leux; Isaac Garcia-Murillas; Roberta Ferraldeschi; David Lorente; Joaquin Mateo; Michael Ong; Timothy A Yap; Udai Banerji; Delila Gasi Tandefelt; Nick Turner; Gerhardt Attard; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2015-06-17       Impact factor: 12.531

5.  Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.

Authors:  Emil Christensen; Karin Birkenkamp-Demtröder; Himanshu Sethi; Svetlana Shchegrova; Raheleh Salari; Iver Nordentoft; Hsin-Ta Wu; Michael Knudsen; Philippe Lamy; Sia Viborg Lindskrog; Ann Taber; Mustafa Balcioglu; Søren Vang; Zoe Assaf; Shruti Sharma; Antony S Tin; Ramya Srinivasan; Dina Hafez; Thomas Reinert; Samantha Navarro; Alexander Olson; Rosalyn Ram; Scott Dashner; Matthew Rabinowitz; Paul Billings; Styrmir Sigurjonsson; Claus Lindbjerg Andersen; Ryan Swenerton; Alexey Aleshin; Bernhard Zimmermann; Mads Agerbæk; Cheng-Ho Jimmy Lin; Jørgen Bjerggaard Jensen; Lars Dyrskjøt
Journal:  J Clin Oncol       Date:  2019-05-06       Impact factor: 44.544

6.  Detection of circulating tumor DNA in early- and late-stage human malignancies.

Authors:  Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

7.  Circulating mutant DNA to assess tumor dynamics.

Authors:  Frank Diehl; Kerstin Schmidt; Michael A Choti; Katharine Romans; Steven Goodman; Meng Li; Katherine Thornton; Nishant Agrawal; Lori Sokoll; Steve A Szabo; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Nat Med       Date:  2007-07-31       Impact factor: 53.440

8.  Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.

Authors:  Karin Birkenkamp-Demtröder; Iver Nordentoft; Emil Christensen; Søren Høyer; Thomas Reinert; Søren Vang; Michael Borre; Mads Agerbæk; Jørgen Bjerggaard Jensen; Torben F Ørntoft; Lars Dyrskjøt
Journal:  Eur Urol       Date:  2016-01-20       Impact factor: 20.096

9.  High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.

Authors:  Pedram Razavi; Bob T Li; David N Brown; Byoungsok Jung; Earl Hubbell; Ronglai Shen; Wassim Abida; Krishna Juluru; Ino De Bruijn; Chenlu Hou; Oliver Venn; Raymond Lim; Aseem Anand; Tara Maddala; Sante Gnerre; Ravi Vijaya Satya; Qinwen Liu; Ling Shen; Nicholas Eattock; Jeanne Yue; Alexander W Blocker; Mark Lee; Amy Sehnert; Hui Xu; Megan P Hall; Angie Santiago-Zayas; William F Novotny; James M Isbell; Valerie W Rusch; George Plitas; Alexandra S Heerdt; Marc Ladanyi; David M Hyman; David R Jones; Monica Morrow; Gregory J Riely; Howard I Scher; Charles M Rudin; Mark E Robson; Luis A Diaz; David B Solit; Alexander M Aravanis; Jorge S Reis-Filho
Journal:  Nat Med       Date:  2019-11-25       Impact factor: 53.440

10.  Clonal evolution of chemotherapy-resistant urothelial carcinoma.

Authors:  Bishoy M Faltas; Davide Prandi; Scott T Tagawa; Ana M Molina; David M Nanus; Cora Sternberg; Jonathan Rosenberg; Juan Miguel Mosquera; Brian Robinson; Olivier Elemento; Andrea Sboner; Himisha Beltran; Francesca Demichelis; Mark A Rubin
Journal:  Nat Genet       Date:  2016-10-17       Impact factor: 38.330

View more
  2 in total

Review 1.  Genomics and Immunomics in the Treatment of Urothelial Carcinoma.

Authors:  Veronica Mollica; Francesco Massari; Alessandro Rizzo; Roberto Ferrara; Arjun K Menta; Jacob J Adashek
Journal:  Curr Oncol       Date:  2022-05-12       Impact factor: 3.109

2.  Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer.

Authors:  Raquel Carrasco; Mercedes Ingelmo-Torres; Ascensión Gómez; Ramón Trullas; Fiorella L Roldán; Tarek Ajami; Davinia Moreno; Leonardo Rodríguez-Carunchio; Antonio Alcaraz; Laura Izquierdo; Lourdes Mengual
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.